[
  {
    "ts": null,
    "headline": "Apple & Amazon earnings, Fed, mortgage rates: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (AAPL) and Amazon (AMZN), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=45cc111297162d113226c7f71109ce6d894df76adefb0289f34a17cc77b422c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761778800,
      "headline": "Apple & Amazon earnings, Fed, mortgage rates: What to Watch",
      "id": 137263516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (AAPL) and Amazon (AMZN), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=45cc111297162d113226c7f71109ce6d894df76adefb0289f34a17cc77b422c7"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet rises as Big Tech earnings pour in",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=a6b99eab8c4bfbcc28d5c35fcb118cc4b150fec31774a293f0ebfc0da211e1d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761770036,
      "headline": "Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet rises as Big Tech earnings pour in",
      "id": 137260210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=a6b99eab8c4bfbcc28d5c35fcb118cc4b150fec31774a293f0ebfc0da211e1d3"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.",
    "summary": "Merck shares have floundered this year, as the company speeds like a whistling locomotive toward the expiration of the patents protecting its megablockbuster cancer immunotherapy Keytruda.  Executives have a shot at reassuring the market on Thursday, when the company reports its third quarter results, but analysts aren’t optimistic.  “We see a choppy 3Q print,” Cantor analyst Carter Gould wrote early this month.",
    "url": "https://finnhub.io/api/news?id=a9c0b56517010d48d9f40881152a0d323b44f87a4199e20eda53d58fa47bdc41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761769800,
      "headline": "Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.",
      "id": 137263688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck shares have floundered this year, as the company speeds like a whistling locomotive toward the expiration of the patents protecting its megablockbuster cancer immunotherapy Keytruda.  Executives have a shot at reassuring the market on Thursday, when the company reports its third quarter results, but analysts aren’t optimistic.  “We see a choppy 3Q print,” Cantor analyst Carter Gould wrote early this month.",
      "url": "https://finnhub.io/api/news?id=a9c0b56517010d48d9f40881152a0d323b44f87a4199e20eda53d58fa47bdc41"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?",
    "summary": "Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.",
    "url": "https://finnhub.io/api/news?id=097fdb27cae818dd810f8eb2d5c71c97dc40c750059eed9191177a899e499180",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761742680,
      "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?",
      "id": 137249538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.",
      "url": "https://finnhub.io/api/news?id=097fdb27cae818dd810f8eb2d5c71c97dc40c750059eed9191177a899e499180"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Boeing stock slips as cash burn improves, Caterpillar and Verizon rise, Enphase tumbles",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=1e78ea517d47939e3b4476ae95897129eae24e54c773264a29d47b7d467a862e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739892,
      "headline": "Earnings live: Boeing stock slips as cash burn improves, Caterpillar and Verizon rise, Enphase tumbles",
      "id": 137247699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=1e78ea517d47939e3b4476ae95897129eae24e54c773264a29d47b7d467a862e"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 29, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
    "url": "https://finnhub.io/api/news?id=e04a198ee7b8fd3da226ac15a92746cfd06fe5daa91e30b3da821d12036cf9a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761735600,
      "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
      "id": 137247955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 29, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
      "url": "https://finnhub.io/api/news?id=e04a198ee7b8fd3da226ac15a92746cfd06fe5daa91e30b3da821d12036cf9a7"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)",
    "summary": "RAHWAY, N.J., October 29, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul",
    "url": "https://finnhub.io/api/news?id=f5d0190ab6bb80d2b1961646a22e78690807fd63d6748ad71905b8f894dee13e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761734700,
      "headline": "European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)",
      "id": 137247956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 29, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul",
      "url": "https://finnhub.io/api/news?id=f5d0190ab6bb80d2b1961646a22e78690807fd63d6748ad71905b8f894dee13e"
    }
  },
  {
    "ts": null,
    "headline": "Merck gets EU green light for Keytruda in head and neck carcinomas",
    "summary": "Merck announces that the European Commission has approved Keytruda as a monotherapy for the treatment of locally advanced and resectable squamous cell carcinoma of the head and neck . The protocol...",
    "url": "https://finnhub.io/api/news?id=ac35be7e22d0b193d07c07fe81d5a13944f6b1ee1471751664fd14b6d1df9cb1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761730696,
      "headline": "Merck gets EU green light for Keytruda in head and neck carcinomas",
      "id": 137247645,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the European Commission has approved Keytruda as a monotherapy for the treatment of locally advanced and resectable squamous cell carcinoma of the head and neck . The protocol...",
      "url": "https://finnhub.io/api/news?id=ac35be7e22d0b193d07c07fe81d5a13944f6b1ee1471751664fd14b6d1df9cb1"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Reports Earnings Tomorrow: What To Expect",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.",
    "url": "https://finnhub.io/api/news?id=e3c8d7e92e292d906b8ffe6d6b94abdb6cc91ed4d14f4e2b12b4c5088dc56d00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761707775,
      "headline": "Merck (MRK) Reports Earnings Tomorrow: What To Expect",
      "id": 137243527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.",
      "url": "https://finnhub.io/api/news?id=e3c8d7e92e292d906b8ffe6d6b94abdb6cc91ed4d14f4e2b12b4c5088dc56d00"
    }
  }
]